Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, China

Status and phase

Enrolling

Phase 2

Conditions

Acute Lymphoblastic Leukemia ALL

Treatments

Biological: Autologous hematopoietic stem cell transplantation combined with CD19-CART

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06608342

IIT2024036

Details and patient eligibility

About

To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

Full description

Enrollment

20 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients with high-risk acute B-lymphoblastic leukemia
Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
Eligible for autologous hematopoietic stem cell transplantation
No major organ dysfunction

Exclusion criteria

Combined with malignant tumors of other organs
With a serious infection that is not under control
Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
Patients who have had an allergic reaction to the drugs used in this study or similar drugs
Other patients deemed unsuitable for inclusion by the investigators